Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Q3 net loss widens to $18.5 million; revenue falls to $1.5 million

Negative Impact 3 of 5 earnings Written later

Aclaris Therapeutics reported third-quarter 2026 results on November 5, 2026, with a net loss of $18.5 million, up from $14.6 million a year earlier, and total revenue of $1.5 million, down from $3.3 million. The company said the revenue decline was mainly due to a sales milestone under the Sun Pharma license agreement recorded in the 2025 periods, while research and development spending rose on the ATI-052 program. Cash, cash equivalents and marketable securities were $204.6 million at September 30, 2026, and the company said this, plus an October 2026 offering, should fund operations through the first half of 2029.

Key points

  • Q3 2026 net loss was $18.5 million versus $14.6 million in Q3 2025; nine-month net loss was $59.8 million versus $45.1 million.
  • Q3 2026 total revenue was $1.5 million versus $3.3 million; nine-month revenue was $5.1 million versus $6.5 million.
  • Q3 2026 R&D expenses were $16.1 million versus $13.0 million, driven mainly by ATI-052 costs.
  • October 2026 offering raised $50.0 million in aggregate gross proceeds; company expects cash to last through the first half of 2029.

The filing

CompanyAclaris Therapeutics, Inc. (ACRS)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:15 AM ET
Accession number0001104659-26-123039

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.